Kiniksa shares surged 27.4% following significant upside in ARCALYST commercial performance and raised full-year revenue guidance, signaling strong execution and expanding market penetration.
- Q2 net revenue reached $243.6 million, up over $29 million sequentially and $85 million versus Q2 2025, marking the largest quarterly increase since launch.
- Full-year 2026 revenue guidance was raised from $945 million to a range of $980 million to $995 million.
- ARCALYST’s prescriber base expanded to over 5,000, with approximately 450 new prescribers added in Q2 and 29% now prescribing for multiple patients.
- Penetration into the multiple recurrence patient population increased to ~21% from ~18% at the end of 2025.
- The company advanced KPL-387 into Phase III trials, targeting a commercial launch in 2028–2029.
Community Discussion